NCT01105702

Temodar (Temozolomide), Bevacizumab, Lithium and Radiation for High Grade Glioma

Temozolomide, Bevacizumab, Lithium and Radiation Treatment for Newly Diagnosed High Grade Glioma: A Phase II Study

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 28 (actual)
• Sponsor: NYU Langone Health · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This pilot phase II trial studies how well giving temozolomide, bevacizumab, lithium carbonate, and radiation therapy works in treating patients with newly diagnosed high grade glioma.

Detailed description

Treatment of high grade glioma (HGG) with anti-angiogenic therapy results in clinical improvement and prolonged progression-free survival (PFS). However, mant patients experience diffuse recurrence and treatment failure. This is a phase II trial testing the feasibility of adding lithium carbonate, previously shown to have anti-invasive properties in HGG, to bevacizumab and chemoradiation following surgical resection of HGG.

Conditions

• Brain Cancer

Interventions

Type	Name	Description
DRUG	Temozolomide
DRUG	Bevacizumab
DRUG	Lithium Carbonate
RADIATION	Radiation

Timeline

• Start date: 2010-05-01
• Primary completion: 2014-04-01
• Completion: 2015-04-01
• First posted: 2010-04-16
• Last updated: 2016-08-04
• Results posted: 2015-11-06

Locations

2 sites across 1 country: United States